Filing summary
Issuer and period: The supplied filing is PharmAthene, Inc.’s Form 10-K for the fiscal year ended December 31, 2011, filed March 8, 2012. It is not an Altimmune, Inc. filing. Although the request labels the period “2011 Q4,” this 10-K reports full-year results; the provided text does not give standalone fourth-quarter financial results.
Business context
PharmAthene was a development-stage biodefense company whose revenue came primarily from U.S. government research and development contracts. Its principal programs were SparVax, an anthrax vaccine; Valortim, an anthrax antibody; and recombinant butyrylcholinesterase (rBChE), a nerve-agent countermeasure. The company had no commercial product sales. It also reported a court award of a 50% share of specified ST-246 net profits, subject to SIGA’s appeal and other conditions.
Financial performance and liquidity
| Metric | 2011 | 2010 |
|---|---|---|
| Contract revenue | $24.3 million | $21.0 million |
| Research and development expense | $21.2 million | $20.9 million |
| General and administrative expense | $14.3 million | $18.0 million |
| Operating loss | $11.7 million | $23.6 million |
| Net loss | $3.8 million | $34.8 million |
| Net loss per share | $0.08 | $1.08 |
| Net cash used in operating activities | $7.8 million | $14.9 million |
| Cash and cash equivalents at year-end | $11.2 million | $11.8 million |
Revenue increased approximately 16%, primarily reflecting higher SparVax activity and milestones. Operating expenses declined, while the reported net loss narrowed substantially. The 2011 net loss included a $7.1 million noncash gain from the change in fair value of derivative instruments and a $0.8 million gain on asset sales; accordingly, net loss was materially smaller than the operating loss.
At December 31, 2011, working capital was approximately $15.0 million and stockholders’ equity was $15.9 million. Total liabilities were $7.0 million, including $1.9 million of derivative liabilities; no convertible notes remained outstanding. Cash, restricted cash and cash equivalents totaled approximately $11.3 million. The company reported no off-balance-sheet arrangements.
Management said cost reductions, cash on hand, collection of year-end receivables, and contract revenue expected in 2012 were anticipated to fund operations and capital requirements through 2012 and into 2013. This was an estimate, not a guarantee: the company had a history of losses and negative operating cash flow and said additional financing might be needed.
Material changes and business developments
- SparVax revenue rose to $19.3 million from $11.7 million. The program recorded $3.5 million of substantive milestone revenue in 2011, compared with $1.8 million in 2010. BARDA funding and future contract modifications remained uncertain, and the government indicated that contract options were unlikely to be exercised.
- Valortim revenue increased to $3.7 million from $3.0 million. Its NIAID development contract ended January 31, 2012; management said near-term government funding was unlikely and uncertain. A prior clinical hold, imposed after adverse reactions in a small trial, was lifted in December 2010.
- The DoD did not continue funding the first-generation Protexia program, which had ended in 2010. PharmAthene shut down related operations and sold its Canadian production facilities in 2011. A new DoD contract provided up to approximately $5.7 million for early-stage rBChE research using a cell-based expression system.
- The company received approximately $5.8 million net proceeds from a June 2011 stock-and-warrant offering. Shares outstanding increased to 48.2 million at year-end from 46.2 million a year earlier.
- The Delaware Court of Chancery awarded PharmAthene 50% of net profits from ST-246 and related products for 10 years after SIGA earns $40 million in net profits. SIGA stated it would appeal; future sales, margins, payment timing, and the outcome of the appeal were uncertain.
Outlook, risks, and unusual items
The company’s prospects depended heavily on government contracts and appropriations, successful development and regulatory approval, and access to external manufacturers and research organizations. Management identified SparVax as the main development focus. FDA approval for the biodefense candidates was expected to rely on the Animal Rule, which requires appropriate animal efficacy evidence and human safety data; success was not assured.
Key risks included possible reductions, delays, or termination of government funding; BARDA’s concerns about SparVax performance, cost ceiling, and schedule; lack of near-term Valortim funding; development, safety, manufacturing scale-up, and regulatory risks; reliance on third parties; competition; and the possibility that SIGA could overturn the ST-246 award on appeal. The company also disclosed a possible $5 million payment to Avecia if a qualifying replacement SparVax contract is received.
Unusual year-over-year earnings effects included the 2011 derivative fair-value gain, the 2010 $4.6 million impairment charge related to Canadian operations, lower 2011 interest expense after convertible notes were converted in 2010, and the 2011 gain from selling Canadian assets. The filing states that the financial statements were audited with an unqualified opinion and that management and the auditor concluded internal control over financial reporting was effective as of year-end.
Most important facts to verify
- Confirm the issuer: this filing is for PharmAthene, Inc., not Altimmune, Inc.
- Review the full audited statements and notes, particularly cash runway, contract receivables, derivative-warrant valuation, and commitments.
- Check subsequent developments on BARDA funding and SparVax contract modifications, and on the end of Valortim’s NIAID contract.
- Verify the status and outcome of SIGA’s appeal, the terms of any resulting ST-246 profit payments, and the assumptions behind potential profitability.
- Assess whether management’s expected funding runway through 2012 and into 2013 was supported by later cash collections, contract awards, and financing.
- Review the potential $5 million Avecia payment trigger and dilution from outstanding warrants, options, and future financing.